US 12,076,352 B2
Immunogenic composition
Christiane Marie-Paule Simone Jeanne Feron, Rixensart (BE); and Sandra Giannini, Rixensart (BE)
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Appl. No. 16/973,471
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
PCT Filed Jun. 18, 2019, PCT No. PCT/EP2019/065974
§ 371(c)(1), (2) Date Dec. 9, 2020,
PCT Pub. No. WO2019/243307, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/686,889, filed on Jun. 19, 2018.
Prior Publication US 2021/0252081 A1, Aug. 19, 2021
Int. Cl. A61K 35/76 (2015.01); C12N 7/00 (2006.01)
CPC A61K 35/76 (2013.01) [C12N 7/00 (2013.01); C12N 2795/00043 (2013.01); C12N 2820/55 (2013.01)] 17 Claims
 
1. An engineered bacteriophage capable of binding to a commensal bacterium and inserting its genome polynucleotide into the commensal bacterium, but incapable of producing progeny, incapable of carrying out a lysogenic cycle and incapable of carrying out a lytic cycle within the commensal bacterium, wherein the engineered bacteriophage comprises a genome polynucleotide including at least one gene encoding at least one heterologous antigen(s) under the control of a promoter and the genome polynucleotide is engineered to delete all genes encoding lytic machinery proteins.